Head-to-head · WeighScore
NuvaHealth vs Omada Health
The verdict
NuvaHealth takes it — 74/100 to 55.6/100.
NuvaHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuvaHealth (nuvahealth.org) is a LegitScript-certified compounded GLP-1 telehealth platform offering compounded semaglutide starting at $159 first-month and compounded tirzepatide starting at $259 first-month.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NuvaHealth | Omada Health |
|---|---|---|
| WeighScore | 74/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #68 | #436 |
| Semaglutide | $139/mo (first-month rate, compounded) | Not disclosed |
| Tirzepatide | $229/mo (first-month rate, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #68 · C
Strengths
- LegitScript Certified seal displayed on the marketing site (the standard third-party telehealth/pharmacy accreditation)
- Free and fast delivery + 24/7 patient support disclosed on the home page
- Newark, DE address suggests a US-incorporated entity (vs offshore)
- $139 first-month price for compounded semaglutide injection is among the cheapest in the US compounded telehealth market
- $229 first-month price for compounded tirzepatide injection sits in the lower-median range
Where it loses points
- Standard ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
- Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
- Pharmacy partners NOT publicly named — material YMYL transparency gap
- Per-state availability NOT enumerated; verify your state ships before purchase
- Lab work + coaching support NOT publicly disclosed
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.